190 related articles for article (PubMed ID: 33351121)
1. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.
Penack O; Peczynski C; Mohty M; Yakoub-Agha I; Styczynski J; Montoto S; Duarte RF; Kröger N; Schoemans H; Koenecke C; Peric Z; Basak GW
Blood Adv; 2020 Dec; 4(24):6283-6290. PubMed ID: 33351121
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
4. Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
Rabian F; Porcher R; Sicre de Fontbrune F; Lioure B; Laplace A; Nguyen S; Tabrizi R; Vigouroux S; Tomowiak C; Maillard N; Suarez F; Delage J; Peffault de Latour R; Socié G;
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1721-1724. PubMed ID: 27246370
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism is associated with graft-
Kekre N; Kim HT; Ho VT; Cutler C; Armand P; Nikiforow S; Alyea EP; Soiffer RJ; Antin JH; Connors JM; Koreth J
Haematologica; 2017 Jul; 102(7):1185-1191. PubMed ID: 28341735
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.
Bensinger WI; Clift R; Martin P; Appelbaum FR; Demirer T; Gooley T; Lilleby K; Rowley S; Sanders J; Storb R; Buckner CD
Blood; 1996 Oct; 88(7):2794-800. PubMed ID: 8839878
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
13. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
14. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.
McDonald GB; Sandmaier BM; Mielcarek M; Sorror M; Pergam SA; Cheng GS; Hingorani S; Boeckh M; Flowers MD; Lee SJ; Appelbaum FR; Storb R; Martin PJ; Deeg HJ; Schoch G; Gooley TA
Ann Intern Med; 2020 Feb; 172(4):229-239. PubMed ID: 31958813
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.
Canaani J; Savani BN; Labopin M; Huang XJ; Ciceri F; Arcese W; Tischer J; Koc Y; Bruno B; Gülbas Z; Blaise D; Maertens J; Ehninger G; Mohty M; Nagler A
Haematologica; 2017 Jun; 102(6):1066-1074. PubMed ID: 28255020
[TBL] [Abstract][Full Text] [Related]
16. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Wadhwa A; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Armenian SH; Arora M; Bhatia S
JAMA Oncol; 2018 Dec; 4(12):e182453. PubMed ID: 30054602
[TBL] [Abstract][Full Text] [Related]
18. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
19. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
